T. van Genechten MD, A. Vanderfaeillie MD, M.A. Azerad MD, D. Kieffer PhD, PharmD, V. Labarque MD, PhD, B. Gulbis MD, PhD, A. Ferster MD, PhD, B. De Wilde MD, PhD
With the increasing prevalence of sickle cell disease patients in Western countries, it is of importance to improve awareness among medical doctors of its complications. To reduce long-term morbidity and mortality, the prompt recognition and treatment of acute complications is important. The existing clinical guideline ‘Follow-up and treatment of patients with sickle cell disease hospitalised for Vaso Occlusive Crisis or infection’, published in 2012 by the Belgian Haematological Society, was revisited to better suit the practical needs of first-line practitioners.
M.A. Azerad MD, F. Debaugnies PharmD, A. Demulder MD, PhD, D. Bron MD, PhD, A. Efira MD
Microvesicles (MV) are since quite recently recognized as forming a unique network between cells. These very little fragments (<1 µm size) are actively released from their parent cells and are able to transfer both cellular and nuclear material. Although active debate remains on how to best detect MV, rendering some results questionable, high MV levels have been reported in aggressive tumours and have been correlated with a poor clinical outcome. Some tumour cell derived MV exhibit strong tissue factor dependent procoagulant activity. Their detection could actually predict the thrombotic risk in selected cancer patients. A growing body of evidence suggests cell microvesicles to be a major link between cancer and thrombosis. Current knowledge on MV in cancer will be reviewed here.